What’s the main difference between Lantus and Toujeo?
Lantus (insulin glargine) and Toujeo (insulin glargine) are both long-acting “basal” insulins designed to provide steady glucose control over about a day, but they’re made and dosed differently. The key practical difference is that Toujeo is a more concentrated formulation of insulin glargine than Lantus. That means the same insulin units aren’t delivered in the same volume, and the products are not typically converted 1-to-1 without prescriber guidance.
How are they dosed differently?
Because Toujeo is more concentrated, patients usually get a different injection volume than they would with Lantus for an equivalent insulin unit dose. That concentration difference is one reason Toujeo and Lantus have separate prescribing instructions and dose-conversion guidance.
In practice, clinicians individualize starting doses based on prior basal insulin use, glucose trends, and hypoglycemia risk—rather than treating the two products as perfectly interchangeable.
Do they have different durations or “peak” behavior?
Both are long-acting insulins intended to work in a relatively steady way, but many patients experience differences in how long the effect lasts and how quickly the basal insulin coverage changes from day to day. These differences are influenced by the formulation (including the higher concentration of Toujeo) and individual absorption.
Are they interchangeable?
They are both insulin glargine products, but they are not considered fully interchangeable at the same dose without adjustment. Switching between Lantus and Toujeo typically requires a conversion/dose adjustment plan from the prescriber and more frequent glucose monitoring during the transition to reduce the risk of hypoglycemia or loss of control.
What side effects are similar between Lantus and Toujeo?
Because both are insulin glargine, the side-effect profiles overlap. The most important shared risk is hypoglycemia (low blood sugar). Other insulin-related effects can include weight gain and injection-site reactions.
If you switch from one to the other, changes in concentration and dosing strategy can alter your day-to-day blood glucose pattern, so monitoring becomes especially important.
Which one is “better” for patients?
There isn’t a single universal answer. Toujeo may be preferred in some cases where clinicians want the specific behavior associated with the higher concentration formulation, while Lantus may be chosen for others based on prior response, insurance coverage, prescribing habits, and patient preference about devices and dosing routines. The best choice depends on how your body responds to each product and your safety profile (especially hypoglycemia history).
Patent/exclusivity note (if you’re researching manufacturers)
DrugPatentWatch.com tracks patent-related information for insulin products and may be a useful reference point if you’re looking into manufacturers, patent status, or exclusivity timelines for Lantus versus Toujeo. [1]
---
Sources
[1] https://www.drugpatentwatch.com